Oxytocin injection (Pitocin) is FDA-approved for induction/stimulation of labor with a medical indication and for control of postpartum bleeding, administered exclusively by controlled IV infusion for labor indications.
obstetric patients
Oxytocin
FDA-approved · specialist care
Vitality
Oxytocin
A hormone approved for use in labor and delivery
FDA-approved for a specific condition · specialist care onlyBoxed warningImportant notice: Pitocin is not indicated for elective induction of labor (induction without a medical reason).
Overview.
Oxytocin is a naturally occurring pituitary hormone long approved as an injectable drug (Pitocin/Syntocinon) for labor induction and control of bleeding after delivery. Intranasal use for social bonding, trust and autism symptoms has grown, but it is not FDA-approved for those uses, and a large 2021 NEJM trial in children and adolescents with autism found no benefit over placebo.
Also known as Pitocin · Syntocinon
The molecule, decoded.
- Sequence
-
C-Y-I-Q-N-C-P-L-G-NH2 (disulfide bridge between Cys1 and Cys6)
- Length
- 9 residues
- Molecular weight
- 1,007.2 g/mol
- Formula
- C43H66N12O12S2
- CAS number
- 50-56-6
- Half-life
- A few minutes (plasma, IV)
- Routes studied
- intravenous infusion (approved, obstetric), intramuscular (approved, postpartum), intranasal (off-label/research, social-cognitive and ASD studies)
- Modifications
- Intramolecular disulfide bond (Cys1-Cys6) forming a six-residue (20-membered) ring with a three-residue C-terminal tail; C-terminal amide (glycinamide)
How it works.
Oxytocin binds the G protein-coupled oxytocin receptor, triggering uterine smooth-muscle contraction (obstetric use) and myoepithelial contraction for milk let-down. In the CNS, oxytocin receptor activation in limbic and cortical regions modulates social cognition, trust, emotion recognition, and pair-bonding behavior, the basis for its intranasal research use.
Evidence · FDA-approved · regulatory-grade trials
What the research shows
A meta-analysis of 12 RCTs (498 patients with ASD) found no significant overall effect of intranasal oxytocin on social impairment or repetitive behaviors; subgroup and dose-response analyses suggested benefit only at higher doses, and the authors concluded there were no consistent beneficial effects.
498 patients with ASD across 12 RCTs
Across 19 clinical trials the combined effect of intranasal oxytocin was small (d=0.32), and only autism studies showed a significant combined effect (d=0.57); in healthy participants it improved emotion recognition and trust, with effects moderated by context, personality and childhood experiences.
healthy and clinical populations, multiple RCTs
A 24-week phase 2 RCT (SOARS-B) of intranasal oxytocin in children and adolescents with autism spectrum disorder found no significant difference from placebo on the primary social-withdrawal outcome.
children and adolescents (3-17y) with ASD, n=290
A small randomized, double-blind crossover trial comparing two doses of intranasal oxytocin, given with a breath-powered device, in adults with ASD found dose-dependent effects on social-cognitive task performance.
17 adult men with ASD
What to know first.
Based on: the FDA-approved label.
Boxed warningImportant notice: Pitocin is not indicated for elective induction of labor (induction without a medical reason).
Reported side effects
- nausea
- in obstetric IV use: uterine hyperstimulation, fetal heart rate changes
Cautions
- Not indicated for elective induction of labor (label 'Important Notice')
- antidiuretic effect: water intoxication with convulsions, especially with large doses infused for long periods or with oral fluids
- uterine hypertonicity, tetanic contraction or rupture with excessive dosage; IV use for labor only in hospital with continuous uterine and fetal heart-rate monitoring
- maternal adverse reactions include anaphylaxis, cardiac arrhythmia, hypertensive episodes, postpartum hemorrhage and subarachnoid hemorrhage
- contraindicated in significant cephalopelvic disproportion, unfavorable fetal positions/presentations, obstetric emergencies favoring surgery, fetal distress when delivery is not imminent, a hyperactive/hypertonic uterus, or when vaginal delivery is contraindicated
- intranasal/off-label use has a much smaller and shorter-duration safety evidence base than the approved obstetric indication
Checked 2026-09
Where it stands.
FDA-approved for a specific condition · specialist care only. Oxytocin is FDA-approved for a specific condition (Oxytocin injection (Pitocin) is FDA-approved to start or strengthen labor when there is a medical reason to do so, and to control bleeding after delivery) and managed through specialist care. RiptideRx doesn’t offer it.
- FDA
- approved (Pitocin/generic oxytocin injection - labor induction/augmentation and postpartum hemorrhage control; original approval predates the modern electronic Drugs@FDA archive)
- Approved products
- Pitocin (FDA, 1980): induction/stimulation of labor with medical indication; control of postpartum uterine bleeding Label
- Compounding
- Intranasal and sublingual oxytocin formulations are not FDA-approved products but are compounded for patient-specific use through licensed 503A pharmacies (compounding of a non-approved route/form of an approved drug's active ingredient), commonly for off-label social or bonding purposes.
- Sport (WADA)
- Not prohibited: oxytocin is not named on the WADA 2026 Prohibited List or Monitoring Program, and as an approved medicine it falls outside S0 Non-Approved Substances. Unchanged for 2027.